menu
Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements, claims Roots Analysis
Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements, claims Roots Analysis
The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks.

To order this 310+page report, which features 110+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

TheUSD 1.9 billion (by 2030) financial opportunity within the continuousmanufacturing market has been analyzed across the following segments:

§ Purpose ofManufacturing

§ In-House

§ Contract service

 

§ Scale of Operation

§ Commercial

§ Preclinical / Clinical

 

§ Type of ContinuousManufacturing related Service

§ API Manufacturing

§ End Productmanufacturing

 

§ Type of Drug Molecule

§ Biologic

§ Small Molecule

 

§ Type of dosage form

§ Solid

§ Liquid

 

§ Key Geographical Regions

§  North America

§  Europe

§  Asia Pacific

 

The ContinuousManufacturing Market (Small Molecules andBiologics), 2020 – 2030.”

 report features the following companies, whichwe identified to be key players in this domain:

§ AbbVie Contract Manufacturing

§ Ajinomoto Bio-Pharma Services

§ Almac

§ Boehringer Ingelheim BioXcellence

§ Cambrex

§ CordonPharma

§ Hovione

§ Kaneka

§ Lonza

§ Patheon

§ SK biotek

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4.  Market Landscape

5. Companies with Expertise in Continuous Manufacturing inNorth America: Profiles

6. Companies with Expertise in Continuous Manufacturing in Europe:Profiles

7. Companies with Expertise in Continuous Manufacturing inAsia-Pacific: Profiles

8. Recent Partnerships and Collaborations

9. Recent Expansions

10. Capacity Analysis

11. Academic Grant Analysis

12. Patent Analysis

13. Initiatives of Companies with In-House ContinuousManufacturing Capabilities

14. Case Study: Modular Facilities in pharmaceutical /Biotechnological Industry

 

15. Case Study: Technology and Equipment Providers

 

16. Case Study: Roadmap for the Adoption of Continuous ManufacturingProcesses

 

17.  Market Forecastand Opportunity Analysis

 

18.  Conclusion

 

19.  ExecutiveInsights

 

20.  Appendix 1:Tabulated Data

 

21.  Appendix 2: Listof Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com